Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10593286 | Bioorganic & Medicinal Chemistry Letters | 2013 | 4 Pages |
Abstract
We report the synthesis and pharmacological characterization of a novel glycosylated analog of a potent and selective endogenous μ-opioid receptor (MOP) agonist, endomorphin-2 (Tyr-Pro-Phe-Phe-NH2, EM-2), obtained by the introduction in position 3 of the tyrosine residue possessing the glucose moiety attached to the phenolic function via a β-glycosidic bond. The improved blood-brain barrier permeability and enhanced antinociceptive effect of the novel glycosylated analog suggest that it may be a promising template for design of potent analgesics. Furthermore, the described methodology may be useful for increasing the bioavailability and delivery of opioid peptides to the CNS.
Keywords
DMFCDMTO-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborateHR-ESI-MSTBTUFMOCTFAEM-2MOP1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphateRP HPLCμ-Opioid receptorendomorphin-2Trifluoroacetic acidIntravenousCNSdimethylformamideBlood–brain barrierBBBcentral nervous systemAntinociceptionhigh-resolution electrospray ionization mass spectrometrySilver triflatePeripheral administrationNaloxone methiodideHATUreversed-phase high-performance liquid chromatography
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jakub Fichna, Marzena Mazur, Daria Grzywacz, Wojciech Kamysz, Renata Perlikowska, Justyna Piekielna, Marta Sobczak, Maciej SaÅaga, Geza Toth, Anna Janecka, Chunqiu Chen, Jacek Olczak,